Montelukast Safety During Pregnancy

Safety Profile of Montelukast in Pregnancy

• Montelukast is classified as FDA Pregnancy Category B, indicating animal studies have not demonstrated risk to the fetus, but adequate controlled studies in pregnant women are limited 1

Clinical Recommendations for Montelukast Use in Pregnancy

• Montelukast can be continued or initiated for recalcitrant asthma during pregnancy, particularly in patients who have shown favorable response prior to pregnancy 2, 3
• The American Congress of Obstetricians and Gynecologists and the American College of Allergy support the use of montelukast in pregnancy when clinically indicated 3
• For asthma control, inhaled medications have been used for many years without documentation of adverse effects on the fetus, making them preferred first-line options 4

Important Considerations and Potential Risks

• About 1% of montelukast passes into breast milk, but extensive metabolism and plasma protein binding are thought to limit infant exposure 3
• For nursing mothers, the benefits of breastfeeding generally outweigh the risk of exposure; consider breastfeeding prior to medication intake to further limit exposure 3
• While montelukast is considered safe for asthma treatment during pregnancy, it is generally not recommended for chronic rhinosinusitis (CRS) maintenance during pregnancy due to lack of efficacy data in this condition 2, 3

Contraindications and Alternatives

• 5-lipoxygenase inhibitors (such as zileuton) should be avoided in both pregnant and lactating mothers 3
• For allergic rhinitis during pregnancy, intranasal corticosteroids (particularly budesonide, which is Pregnancy Category B) or sodium cromolyn may be preferred options 1, 5

Monitoring Recommendations

• Regular monitoring of asthma control is essential during pregnancy, as poorly controlled asthma poses greater risks to maternal and fetal health than medication use 4
• Montelukast should be used at the lowest effective dose during pregnancy 1, 5

Montelukast Use During Pregnancy

Safety Classification and Evidence Base

• The European Respiratory Society and Thoracic Society of Australia and New Zealand classify montelukast as "probably safe" with limited data suggesting no significantly increased risk of malformations, though the number of exposed women remains insufficient to ensure complete fetal safety 6, 7
• Cases of limb reduction defects have been reported in post-marketing surveillance, though a causal relationship has not been established 6

Clinical Recommendations for Asthma Management

• Consider initiating montelukast for recalcitrant asthma when conventional inhaled medications fail to achieve adequate control 6
• Inhaled corticosteroids (particularly budesonide) remain first-line therapy, with decades of safety data showing no adverse fetal effects 8, 9
• Short-acting beta-agonists like albuterol have extensive reassuring pregnancy data 8, 9

Important Clinical Context

• Asthma exacerbations during pregnancy can lead to severe fetal problems and should be managed aggressively 8, 9
• The risk of untreated severe asthma exceeds any theoretical medication risk 8, 9

Preferred Alternatives

• The American College of Allergy, Asthma, and Immunology supports the use of inhaled corticosteroids as first-line therapy for asthma management during pregnancy 8, 9

Safety and Use of Montelukast for Asthma in Pregnancy

Safety Evidence

• Montelukast is considered “possibly safe” during pregnancy by the European Respiratory Society and the Thoracic Society of Australia & New Zealand, with limited data showing no statistically significant rise in congenital malformations. 10
• A large prospective cohort of 180 pregnancies exposed to montelukast reported only one major congenital malformation (0.6%), a rate that does not exceed the 1‑3 % baseline risk in the general population. 10 – prospective study
• In a Danish population‑based study of 827 montelukast‑exposed pregnancies, the adjusted odds ratio for major congenital anomalies was 1.4 (95 % CI 0.9‑2.3) for montelukast alone and 1.0 (95 % CI 0.6‑1.8) when combined with other asthma medications, indicating no increased risk. 10 – population cohort
• A Japanese prospective cohort of 231 pregnancies exposed to leukotriene‑receptor antagonists (including 122 montelukast exposures) found a major anomaly rate of 1.9 % and an adjusted odds ratio of 0.78 (95 % CI 0.23‑2.05), showing no significant association with congenital defects. 10 – prospective cohort

Clinical Recommendations

• Continue montelukast during pregnancy if it provided good asthma control before conception, as endorsed by the American College of Obstetricians and Gynecologists and the American College of Allergy. 10 – expert consensus
• Initiate montelukast for recalcitrant asthma when standard inhaled therapies (inhaled corticosteroids and short‑acting β‑agonists) fail to achieve adequate control. 10 – guideline recommendation
• Use montelukast as second‑line therapy after inhaled corticosteroids and short‑acting β‑agonists, according to the European Respiratory Society. 10 – guideline recommendation

First‑Line and Adjunct Therapies in Pregnancy

• Short‑acting β‑agonists (e.g., albuterol) have extensive reassuring safety data in pregnancy and are unlikely to cause structural fetal anomalies. 11 – large observational evidence

Risks of Untreated or Poorly Controlled Asthma

• Untreated or inadequately controlled asthma is linked to higher rates of perinatal mortality, pre‑eclampsia, preterm birth, and low‑birth‑weight infants. 12 – clinical outcome data
• Maternal hypoxia from severe asthma exacerbations has well‑described adverse effects on the fetus, reinforcing the need for aggressive asthma management. [11][12] – well‑documented pathophysiology

Montelukast Use in Pregnancy and Lactation: Evidence‑Based Guidelines

Safety Classification

• Montelukast is classified as FDA Pregnancy Category B, indicating no fetal risk demonstrated in animal studies and reassuring human safety data with no increase in major congenital malformations; the American Congress of Obstetricians and Gynecologists and the American College of Allergy endorse its use when clinically indicated, especially for recalcitrant asthma【13】.

Clinical Indications

Asthma

• Continue montelukast throughout pregnancy when it provided good asthma control before conception, as maintaining effective therapy reduces maternal and fetal risks【13】.
• Initiate montelukast for recalcitrant asthma during pregnancy only after standard inhaled therapies (inhaled corticosteroids and short‑acting β‑agonists) have failed to achieve adequate control【13】.

Allergic Rhinitis & Chronic Rhinosinusitis

• Avoid montelukast for chronic rhinosinusitis maintenance during pregnancy due to lack of efficacy data in this condition【13】.
• For allergic rhinitis in pregnant patients, prefer intranasal corticosteroids (e.g., budesonide) or sodium cromolyn as first‑line therapy, per allergy society guidance【14】.

Breastfeeding

• Approximately 1 % of a maternal dose of montelukast is transferred into breast milk, but extensive metabolism and high plasma protein binding limit infant exposure【13】.
• The benefits of breastfeeding generally outweigh the potential risk of infant exposure to montelukast【13】.
• When feasible, schedule breastfeeding before taking the medication to further minimize infant exposure【13】.

Treatment Algorithm for Pregnant Patients

• Well‑controlled asthma on montelukast before pregnancy: Continue montelukast throughout gestation【13】.
• Inadequately controlled asthma despite first‑line inhaled therapy: Add montelukast as a second‑line agent after inhaled corticosteroids and short‑acting β‑agonists have been optimized【13】.
• Allergic rhinitis without asthma: Use intranasal corticosteroids or sodium cromolyn rather than montelukast【14】.